In vitro studies demonstrate Pfizer and BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with key mutations present in U.K. and South African variants

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from in vitro neutralization studies of sera from individuals vaccinated with the Pfizer-BioNTech COVID-19 vaccine. The sera neutralized SARS-CoV-2 with key mutations present in the United Kingdom (U.K.) and South Africa variants, as measured by studies conducted by Pfizer and the University of Texas Medical Branch (UTMB).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news